Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat in EGFR-TKI Resistant Lung Adenocarcinoma
NCT06818955Phase 2Not yet recruiting
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of orlistat in lung adenocarcinoma. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
orlistat
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06818955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818955.